[Federal Register Volume 59, Number 31 (Tuesday, February 15, 1994)] [Unknown Section] [Page 0] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 94-3505] [[Page Unknown]] [Federal Register: February 15, 1994] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Prospective Grant of Co-Exclusive License: Type Alpha Platelet- Derived Growth Factor (PDGF) Receptor Gene AGENCY: National Institutes of Health, Public Health Service, DHHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: This is notice in accordance with 15 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a co-exclusive world-wide license to practice the invention embodies in U.S. Patent Applications SN 07/308,282 and SN 07/915,884, both entitled ``Type Alpha Platelet-Derived Growth Factor Receptor Gene'' to Targeted Genetics Corporation, of Seattle, Washington. The patent rights in this invention have been assigned to the United States of America. The prospective license will be royalty-bearing, will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7, and is expected to be co-exclusive with one other party, COR Therapeutics, Inc. It is anticipated that this license will be limited to gene therapy treatment of cardiovascular disease. Publication of this notice should be considered a modification of an earlier notice ``Prospective Grant of Exclusive License: Type Alpha Platelet-Derived Growth Factor'' (Vol. 58, No. 16, Wednesday, January 17, 1993, page 6287). This prospective co-exclusive license may be granted unless, within 60 days from the date of this published notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7. The patent application describes novel DNA segments that encode platelet-derived growth factor (PDGF) receptors that may be useful in therapies for conditions involving abnormal processes involving PDGF and its receptors. In particular, bioassay methods for detecting the expression of genes related to these DNA segments are effective in the identification of various classes of tumor cells, genetic defects in connective tissue growth, or in the healing response. ADDRESSES: Requests for a copy of this patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Mr. Steven M. Ferguson, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, Box OTT, Bethesda, MD 20892. Telephone: (301) 496-7735; Facsimile: (301) 402-0220. Applications for a license filed in response to this notice will be treated as objections to the grant of the contemplated license. Only written comments and/or applications for a license which are received by NIH within sixty (60) days of this notice will be considered. Dated: February 7, 1994. Donald P. Christoferson, Acting Director, Office of Technology Transfer. [FR Doc. 94-3505 Filed 2-14-94; 8:45 am] BILLING CODE 4140-01-M